Nature reports on a co-folding model trained on more than 20,000 proprietary protein structures from pharmaceutical companies, and how it compares with AlphaFold-like models that use only public data.
Introducing Apheris Foundry: federated drug discovery models, customized to your data and accessible to your agents
Affinity scores should depend on how a compound binds. ApherisAffinity uses structurally validated training data, a geometry-aware affinity head and disrupted-binding-site negatives, so its predictions respond to target changes and rank compounds in a real discovery series better than Boltz‑2 and Nesso‑1.
Apheris federated networks for drug discovery and European healthcare studies can now run on T-Systems’ sovereign infrastructure, with patient data staying inside each hospital.
NEWSLETTER
A quaterly briefing on operationalizing and customizing co-folding, ADMET and antibody developability models. Written by Robin Röhm, co-founder and CEO at Apheris.
